In another in vivo study, ivacaftor/lumacaftor treatment of CF patients increased renal pendrin (SLC26A4)-mediated HCO3− excretion through correction of F508del-CFTR activity in the β-intercalated cells of the collecting duct [37]. The gene discussed is SLC26A4; the disease is cystic fibrosis.